Cargando…

Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in initial trials. This article reviews the preclinical evidenc...

Descripción completa

Detalles Bibliográficos
Autor principal:	Harvey, R D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685326/ https://www.ncbi.nlm.nih.gov/pubmed/24690569 http://dx.doi.org/10.1038/clpt.2014.74

Ejemplares similares

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
por: Momtaz, Parisa, et al.
Publicado: (2014)

The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients
por: Wu, Bing, et al.
Publicado: (2023)

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
por: Curti, Brendan D, et al.
Publicado: (2021)

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
por: Kim, Kyung Hwan, et al.
Publicado: (2020)

Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer
por: Qu, Yanli, et al.
Publicado: (2021)

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
por: Planes-Laine, Gabrielle, et al.
Publicado: (2019)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
por: Pathak, Ranjan, et al.
Publicado: (2020)

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
por: Tanaka, Ichidai, et al.
Publicado: (2021)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

Effectiveness of immunological agents in non‐small cell lung cancer
por: Rekulapelli, Akhil, et al.
Publicado: (2022)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
por: Karimi, Nastaran, et al.
Publicado: (2023)

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies
por: Vermeij, R., et al.
Publicado: (2011)

Cancer immunotherapies targeting the PD-1 signaling pathway
por: Iwai, Yoshiko, et al.
Publicado: (2017)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD‐1 antibodies
por: Levingston, Corinne A., et al.
Publicado: (2017)

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer
por: Li, Jia-Xin, et al.
Publicado: (2019)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors for Non–Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management
por: Davies, Marianne J.
Publicado: (2019)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
por: Santarpia, Mariacarmela, et al.
Publicado: (2020)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
por: Kumar, Sunny, et al.
Publicado: (2022)

Beyond PD-L1 Markers for Lung Cancer Immunotherapy
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2019)

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
por: Liu, Bingshan, et al.
Publicado: (2017)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment
por: Yu, Xin, et al.
Publicado: (2022)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Trends and advances in tumor immunology and lung cancer immunotherapy
por: Aldarouish, Mohanad, et al.
Publicado: (2016)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Aspirin‐targeted PD‐L1 in lung cancer growth inhibition
por: Zhang, Yixiang, et al.
Publicado: (2020)

Clinical Immunology
por: Edgar, J David M
Publicado: (2011)

Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy
por: Chuckran, Christopher A, et al.
Publicado: (2020)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
por: Pandey, Pratibha, et al.
Publicado: (2022)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dll4eq9328qs0744044u1he57r